Adelaide J. Kwon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Adelaide J. Kwon has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Olga K. Weinberg
Department of Pathology, University of Texas Southwestern Medical Center, Dallas, USA
3 shared publications Prasad Koduru
Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX
3 shared publications- Weina Chen
Department of Pathology University of Texas Southwestern Medical Center Dallas Texas USA
3 shared publications Franklin Fuda
Department of Pathology University of Texas Southwestern Medical Center Dallas Texas USA
2 shared publicationsJeffrey Gagan
Department of Pathology University of Texas Southwestern Medical Center Dallas Texas USA
2 shared publicationsMiguel Cantu
Department of Pathology University of Texas Southwestern Medical Center Dallas Texas USA
2 shared publications
Latest Publications
- Open Access
- 5 September 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (12) , 3036-3042
Clonally Related Chronic Lymphocytic Leukemia and Malignant Histiocytic Neoplasm (Histiocytic Sarcoma With Overlapping Langerhans Cell Phenotype): Divergent Evolution From a Shared Cell‐Of‐Origin
- 5 September 2026
- Published by Wiley in American Journal of Hematology
- Vol. 101 (12) , 3036-3042
Open AccessClonally Related Chronic Lymphocytic Leukemia and Malignant Histiocytic Neoplasm (Histiocytic Sarcoma With Overlapping Langerhans Cell Phenotype): Divergent Evolution From a Shared Cell‐Of‐Origin
- Open Access
- 1 May 2026
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (3) , 100241
Deletion 11q, monosomy 13, and deletion 13q in noncomplex karyotype acute myeloid leukemia
- 1 May 2026
- Published by Elsevier in Blood Neoplasia
- Vol. 3 (3) , 100241
Open AccessDeletion 11q, monosomy 13, and deletion 13q in noncomplex karyotype acute myeloid leukemia
- 26 May 2025
- Published by Wiley in International Journal of Laboratory Hematology
Trisomy 8 in De Novo Acute Myeloid Leukemia Lacking MDS‐Related Cytogenetics Does Not Significantly Influence Survival
Introduction: The 2022 WHO and ICC classifications identify MDS‐related cytogenetic abnormalities and secondary gene mutations (SM) that in de novo disease are diagnostic of myelodysplasia‐related AML, which confers a poorer prognosis. While most MDS‐related abnormalities overlap between the two classifications, trisomy 8 (+8) is unique to the ICC and has not been previously included as an MDS‐related abnormality. In light of this, we sought to determine the prognostic significance of +8 as an MDS‐related abnormality in patients with de novo AML lacking other MDS‐related cytogenetics.Methods: We identified 337 patients with de novo AML lacking MDS‐related cytogenetics other than +8 and analyzed clinicopathologic outcomes, overall survival (OS), and relapse‐free survival (RFS). Two groups were identified: AML with SM (n = 195, 57.9%) and AML without SM (n = 142, 42.1%). Fifty‐nine (17.5%) patients had +8; 39 (66.1%) of these had at least one SM, while 20 (33.9%) did not.Results: Among patients treated with induction or hypomethylating agents (n = 317), OS and RFS were significantly shorter in patients with SM than without (OS: p = 0.001, RFS: p = 0.0004) but not significantly different between patients with and without +8 (OS: p = 0.15, RFS: p = 0.35). Similarly, when cases were limited to those with SM (n = 179), no significant difference in OS or RFS was observed between patients with and without +8 (OS: p = 0.21, RFS: p = 0.30). There was no significant association between +8 and SM (p = 0.15).Conclusion: In our cohort, unlike MDS‐related SM, trisomy 8 does not influence OS or RFS, despite its inclusion in the ICC as an MDS‐related abnormality.
- 26 May 2025
- Published by Wiley in International Journal of Laboratory Hematology
Trisomy 8 in De Novo Acute Myeloid Leukemia Lacking MDS‐Related Cytogenetics Does Not Significantly Influence Survival
Introduction: The 2022 WHO and ICC classifications identify MDS‐related cytogenetic abnormalities and secondary gene mutations (SM) that in de novo disease are diagnostic of myelodysplasia‐related AML, which confers a poorer prognosis. While most MDS‐related abnormalities overlap between the two classifications, trisomy 8 (+8) is unique to the ICC and has not been previously included as an MDS‐related abnormality. In light of this, we sought to determine the prognostic significance of +8 as an MDS‐related abnormality in patients with de novo AML lacking other MDS‐related cytogenetics.Methods: We identified 337 patients with de novo AML lacking MDS‐related cytogenetics other than +8 and analyzed clinicopathologic outcomes, overall survival (OS), and relapse‐free survival (RFS). Two groups were identified: AML with SM (n = 195, 57.9%) and AML without SM (n = 142, 42.1%). Fifty‐nine (17.5%) patients had +8; 39 (66.1%) of these had at least one SM, while 20 (33.9%) did not.Results: Among patients treated with induction or hypomethylating agents (n = 317), OS and RFS were significantly shorter in patients with SM than without (OS: p = 0.001, RFS: p = 0.0004) but not significantly different between patients with and without +8 (OS: p = 0.15, RFS: p = 0.35). Similarly, when cases were limited to those with SM (n = 179), no significant difference in OS or RFS was observed between patients with and without +8 (OS: p = 0.21, RFS: p = 0.30). There was no significant association between +8 and SM (p = 0.15).Conclusion: In our cohort, unlike MDS‐related SM, trisomy 8 does not influence OS or RFS, despite its inclusion in the ICC as an MDS‐related abnormality.
- 21 January 2025
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 47 (3) , 445-453
Clinicopathologic and Molecular Characterization of NUP98‐Rearranged Acute Leukemias
Introduction: NUP98 rearrangements are rare in acute leukemias and portend a poor prognosis.Methods: This study explored clinicopathologic and molecular features of five patients with NUP98 rearranged (NUP98‐r) acute leukemias, including three females and two males with a median age of 34 years.Results: NUP98 fusion partners were associated with distinctive leukemia characteristics and biology. Three patients had NUP98::NSD1‐r acute myeloid leukemia (AML, all cytogenetically cryptic and with concomitant FLT3‐ITD) and unfavorable prognoses (in two patients), one patient had NUP98::HOXA9‐r AML with morphologic and immunophenotypic features resembling acute promyelocytic leukemia, and lastly, one patient had previously underreported NUP98::MLLT1‐r B/T mixed phenotype acute leukemia. After a median follow‐up of 24.7 months, median overall survival was 30 months and three of five patients (60%) remained in complete remission at the last follow‐up.Conclusion: Our study expands the clinical and molecular spectrum of NUP98‐r acute leukemias and recommends FISH testing for NUP98 rearrangement on those leukemia cases without recurrent gene rearrangements and/or normal karyotype followed by molecular confirmation to improve timely diagnosis and clinical management.
- 21 January 2025
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 47 (3) , 445-453
Clinicopathologic and Molecular Characterization of NUP98‐Rearranged Acute Leukemias
Introduction: NUP98 rearrangements are rare in acute leukemias and portend a poor prognosis.Methods: This study explored clinicopathologic and molecular features of five patients with NUP98 rearranged (NUP98‐r) acute leukemias, including three females and two males with a median age of 34 years.Results: NUP98 fusion partners were associated with distinctive leukemia characteristics and biology. Three patients had NUP98::NSD1‐r acute myeloid leukemia (AML, all cytogenetically cryptic and with concomitant FLT3‐ITD) and unfavorable prognoses (in two patients), one patient had NUP98::HOXA9‐r AML with morphologic and immunophenotypic features resembling acute promyelocytic leukemia, and lastly, one patient had previously underreported NUP98::MLLT1‐r B/T mixed phenotype acute leukemia. After a median follow‐up of 24.7 months, median overall survival was 30 months and three of five patients (60%) remained in complete remission at the last follow‐up.Conclusion: Our study expands the clinical and molecular spectrum of NUP98‐r acute leukemias and recommends FISH testing for NUP98 rearrangement on those leukemia cases without recurrent gene rearrangements and/or normal karyotype followed by molecular confirmation to improve timely diagnosis and clinical management.